VRDN (Viridian Therapeutics) Shiller PE Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRDN Viridian Therapeutics Inc VRDN
47 GF Score
Price $22.09
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Viridian Therapeutics  (NAS:VRDN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Viridian Therapeutics Shiller PE Ratio Related Terms


Viridian Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Shiller PE Ratio Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VRDN vs BHVN, AGIO, SION: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Viridian Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Shiller PE Ratio falls into.


VRDN
47GF Score
Viridian Therapeutics Inc VRDN
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Viridian Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Viridian Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.05/333.9520*333.9520
=-1.050

Current CPI (Jun. 2026) = 333.9520.

Viridian Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -38.250 241.428 -52.909
201612 -115.200 241.432 -159.346
201703 -9.000 243.801 -12.328
201706 -5.100 244.955 -6.953
201709 -4.050 246.819 -5.480
201712 -4.350 246.524 -5.893
201803 -2.700 249.554 -3.613
201806 -4.350 251.989 -5.765
201809 -4.350 252.439 -5.755
201812 -4.950 251.233 -6.580
201903 -5.700 254.202 -7.488
201906 -4.350 256.143 -5.671
201909 -5.400 256.759 -7.023
201912 -4.650 256.974 -6.043
202003 -2.650 258.115 -3.429
202006 -1.820 257.797 -2.358
202009 -1.480 260.280 -1.899
202012 -23.070 260.474 -29.578
202103 -2.910 264.877 -3.669
202106 -2.210 271.696 -2.716
202109 -1.250 274.310 -1.522
202112 -1.210 278.802 -1.449
202203 -0.980 287.504 -1.138
202206 -1.060 296.311 -1.195
202209 -0.860 296.808 -0.968
202212 -1.130 296.797 -1.271
202303 -1.610 301.836 -1.781
202306 -1.270 305.109 -1.390
202309 -1.090 307.789 -1.183
202312 -1.350 306.746 -1.470
202403 -0.590 312.332 -0.631
202406 -0.770 314.175 -0.818
202409 -0.880 315.301 -0.932
202412 -0.810 315.605 -0.857
202503 -0.870 319.799 -0.909
202506 -1.000 322.561 -1.035
202509 -0.340 324.800 -0.350
202512 -1.080 324.054 -1.113
202603 -0.900 330.213 -0.910
202606 -1.050 333.952 -1.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viridian Therapeutics Business Description

Other Exchanges 0K1R:UK1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
47GF Score

Get the complete analysis for VRDN

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.09
Price